Should Obese Patients Be Included In Every Drug Development Program?
Executive Summary
FDA officials question whether modeling tools can predict which drugs have different disposition in obese populations. They say physiologically-based pharmacokinetic data cannot be used as a surrogate for actual clinical trial data at this time.